InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Recombinant human IL-1β | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
| QUANTI-Blue™ | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
| IL-1β Reporter HEK 293 Cells | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
| TLR4 agonist preparation - MPLA-SM | Matured Tolerogenic Dendritic Cells Effectively Inhibit Autoantigen Specific ... | 2021 | Front Immunol | Jansen M.A. et al. | DOI: 10.3389/fimmu.2019.02068 |
| J774-Dual™ Cells | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| LyoVec™ | Inhibitor of growth protein 3 epigenetically silences endogenous retroviral e... | 2021 | Nucleic Acids Res | Song Y. et al. | DOI: 10.1093/nar/gkab1070 |
| Poly(I:C) (HMW) / LyoVec™ | Inhibitor of growth protein 3 epigenetically silences endogenous retroviral e... | 2021 | Nucleic Acids Res | Song Y. et al. | DOI: 10.1093/nar/gkab1070 |
| THP1-Dual™ Cells | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| QUANTI-Blue™ | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| Recombinant human IFN-α | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| 2'3'-cGAMP | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| 5'ppp-dsRNA | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| QUANTI-Luc™: Luciferase Detection Reagent | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
| Puromycin | MAGEH1 interacts with GADD45G and induces renal tubular cell apoptosis. | 2021 | PLoS One | Shin G.T. et al. | DOI: 10.1371/journal.pone.0260135 |
| MycoStrip™ - Mycoplasma Detection Kit | MAGEH1 interacts with GADD45G and induces renal tubular cell apoptosis. | 2021 | PLoS One | Shin G.T. et al. | DOI: 10.1371/journal.pone.0260135 |
| TLR4 agonist preparation - MPLA-SM | An allergen-fused dendritic cell-binding peptide enhances in vitro proliferat... | 2022 | Vet Immunol Immunopathol | Ziegler A et al. | DOI: 10.1016/j.vetimm.2021.110351 |
| ODN D-SL03 | An allergen-fused dendritic cell-binding peptide enhances in vitro proliferat... | 2022 | Vet Immunol Immunopathol | Ziegler A et al. | DOI: 10.1016/j.vetimm.2021.110351 |
| Puromycin | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal infla... | 2021 | Nat Commun | Ryzhakov G. et al. | DOI: 10.1038/s41467-021-27038-5 |
| WGP - Whole Glucan Particles | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal infla... | 2021 | Nat Commun | Ryzhakov G. et al. | DOI: 10.1038/s41467-021-27038-5 |
| Recombinant anti-mouse PD-1 antibody - Clone RMP1-14 (D265A) | Sharpening up tumor microenvironment to enhance the efficacy of immune checkp... | 2021 | Cancer Immunol Immunother | Tseng J.C. et al. | DOI: 10.1007/s00262-021-03062-8 |